European Society for Medical Oncology (ESMO) 2018 Congress - X4 Pharmaceuticals

European Society for Medical Oncology (ESMO) 2018 Congress

European Society for Medical Oncology (ESMO) 2018 Congress

October 2018

Combination Therapy with the CXCR4 Inhibitor X4P-001 and Nivolumab Demonstrates Preliminary Anti-tumor Activity in RCC Patients that are Unresponsive to Nivolumab Alone

© Copyright 2024 X4 Pharmaceuticals. All Rights Reserved. Terms of Use | Privacy | Compliance and Ethics